Legal & General Group
AST

Legal & General Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Legal & General Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,348
Closed -$6K – 3482
2018
Q1 		$6K Hold
4,348
– – ﹤0.01% 3254
2017
Q4 		$10K Hold
4,348
– – ﹤0.01% 3235
2017
Q3 		$15K Hold
4,348
– – ﹤0.01% 3236
2017
Q2 		$15K Hold
4,348
– – ﹤0.01% 3268
2017
Q1 		$15K Buy
4,348
+1,937
+80% +$7.53K ﹤0.01% 3151
2016
Q4 		$11K Buy
+2,411
New +$9.95K ﹤0.01% 3209

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Legal & General Group's AST Position: Q2 2018 in Review

Legal & General Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 4,348 shares — an estimated $6K sold.

Legal & General Group first reported a position in AST in Q4 2016 and held it in 6 quarters. The position peaked at $15K in Q3 2017. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

  • Legal & General Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
  • Legal & General Group sold 4,348 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $6K.
  • Legal & General Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 6 quarters.
  • Legal & General Group's Asterias Biotherapeutics Inc. Series A position peaked at $15K in Q3 2017.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on Legal & General Group's 13F filing for Q2 2018, filed 10 Aug 2018.